TNFSF10 and prostate cancer: Thus, prostate cancer cells with PTEN mutations or deletions have elevated PI3K and AKT/PKB activation levels, which is likely to bestow survival benefits onto these cells when challenged by physiological surveillance mechanisms or treatment with chemotherapeutic agents or biologicals such as TRAIL.